Evidence map›Paper›PMID 37291656›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2023

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial.

Samuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, Ian D Davis, Andrew M Scott, Rodney J Hicks, Ur Metser, Sue Chua, Reena Davda, Shonit Punwani and 8 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer Current and emerging strategies.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Samuel TremblayCHU de Québec and Université Laval, Québec, Québec, Canada.
Mofarej AlhogbaniCHU de Québec and Université Laval, Québec, Québec, Canada.
Andrew WeickhardtAustin Health and University of Melbourne, Olivia Newton-John Cancer Research Institute, La Trobe University, Melbourne, Australia.
Ian D DavisMonash University Eastern Health Clinical School, Box Hill, VIC, Australia.
Andrew M ScottAustin Health and University of Melbourne, Olivia Newton-John Cancer Research Institute, La Trobe University, Melbourne, Australia.
Rodney J HicksPeter MacCallum Cancer Centre, Melbourne, Australia.
Ur MetserUniversity of Toronto, Toronto, ON, Canada.
Sue ChuaRoyal Marsden Hospital, London, UK.
Reena DavdaUniversity College London, London, UK.
Shonit PunwaniSt. Vincent's Hospital, Sydney, NSW, Australia.
Heather PayneLondon Health Sciences Centre, London, ON, Canada.
Nina TunariuRoyal Marsden Hospital, London, UK.
Bao HoSt. Vincent's Hospital, Sydney, NSW, Australia.
Sympascho YoungLondon Health Sciences Centre, London, ON, Canada.
Mahukpe Narcisse Ulrich SingboCHU de Québec and Université Laval, Québec, Québec, Canada.
Glenn BaumanLondon Health Sciences Centre, London, ON, Canada.
Louise EmmettSt. Vincent's Hospital, Sydney, NSW, Australia.
Frédéric PouliotCHU de Québec and Université Laval, Québec, Québec, Canada. frederic.pouliot@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0002-6651-1079
Université Laval · CALondon Health Sciences Centre · CASt Vincent's Hospital Sydney · AULa Trobe University · AURoyal Marsden Hospital · GBEastern Health · AUPeter MacCallum Cancer Centre · AUUniversity College London · GBUniversity of Toronto · CA

Funding

Movember Foundation Movember Foundation
6 · The paper itself

Abstract

backgroundThe impact of molecular imaging (MI) on patient management after biochemical recurrence (BCR) following radical prostatectomy has been described in many studies. However, it is not known if MI-induced management changes are appropriate. This study aimed to determine if androgen deprivation therapy (ADT) management plan is improved by MI in patients who are candidates for salvage radiation therapy.

methodsData were analyzed from the multicenter prospective PROPS trial evaluating PSMA/Choline PET in patients being considered for salvage radiotherapy (sRT) with BCR after prostatectomy. We compared the pre- and post-MI ADT management plans for each patient and cancer outcomes as predicted by the MSKCC nomogram. A higher percentage of predicted BCR associated with ADT treatment intensification after MI was considered as an improvement in a patient's management.

resultsSeventy-three patients with a median PSA of 0.38 ng/mL were included. In bivariate analysis, a positive finding on MI (local or metastatic) was associated with decision to use ADT with an odds ratio of 3.67 (95% CI, 1.25 to 10.71; p = 0.02). No factor included in the nomogram was associated with decision to use ADT. Also, MI improved selection of patients to receive ADT based on predicted BCR after sRT : the predicted nomogram 5-year biochemical-free survivals were 52.5% and 43.3%, (mean difference, 9.2%; 95% CI 0.8 to 17.6; p = 0.03) for sRT alone and ADT±sRT subgroups, while there was no statistically significant difference between subgroups before MI.

conclusionsPSMA and/or Choline PET/CT before sRT can potentially improve patient ADT management by directing clinicians towards more appropriate intensification.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsCholineHumansMaleNeoplasm Recurrence, LocalPatient SelectionPositron Emission Tomography Computed TomographyProspective StudiesProstatectomyProstate-Specific AntigenRetrospective StudiesAndrogen AntagonistsCholineProstate-Specific AntigenBiochemical recurrenceCholineMolecular imagingProstate cancerPSMA

Identifiers

PMID37291656
PMCPMC10249189
OpenAlexW4379966813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.